Gulf International Bank UK Ltd Raises Holdings in Edwards Lifesciences Corp (EW)

Share on StockTwits

Gulf International Bank UK Ltd grew its position in shares of Edwards Lifesciences Corp (NYSE:EW) by 7.8% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 71,532 shares of the medical research company’s stock after purchasing an additional 5,202 shares during the quarter. Gulf International Bank UK Ltd’s holdings in Edwards Lifesciences were worth $12,453,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of EW. Private Capital Group LLC purchased a new position in shares of Edwards Lifesciences during the second quarter worth about $112,000. Centaurus Financial Inc. purchased a new position in shares of Edwards Lifesciences during the second quarter worth about $114,000. LFA Lugano Financial Advisors SA purchased a new position in shares of Edwards Lifesciences during the third quarter worth about $121,000. Signet Financial Management LLC purchased a new position in shares of Edwards Lifesciences during the second quarter worth about $136,000. Finally, Ropes Wealth Advisors LLC grew its holdings in shares of Edwards Lifesciences by 187.4% during the second quarter. Ropes Wealth Advisors LLC now owns 1,006 shares of the medical research company’s stock worth $146,000 after buying an additional 656 shares during the last quarter. 82.71% of the stock is currently owned by institutional investors.

In other news, VP Catherine M. Szyman sold 700 shares of the business’s stock in a transaction on Monday, October 15th. The shares were sold at an average price of $142.64, for a total transaction of $99,848.00. Following the completion of the sale, the vice president now directly owns 27,772 shares of the company’s stock, valued at approximately $3,961,398.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Michael A. Mussallem sold 32,900 shares of the business’s stock in a transaction on Wednesday, September 12th. The shares were sold at an average price of $144.02, for a total transaction of $4,738,258.00. Following the sale, the chief executive officer now directly owns 76,026 shares of the company’s stock, valued at $10,949,264.52. The disclosure for this sale can be found here. Insiders have sold a total of 116,511 shares of company stock valued at $16,634,402 over the last 90 days. Insiders own 1.84% of the company’s stock.

EW has been the topic of a number of research reports. Guggenheim lowered Edwards Lifesciences from a “buy” rating to a “neutral” rating in a report on Tuesday, October 2nd. Zacks Investment Research raised Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $185.00 price target on the stock in a report on Wednesday, September 26th. ValuEngine raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Wednesday, September 19th. SunTrust Banks raised their price target on Edwards Lifesciences to $200.00 and gave the stock a “buy” rating in a report on Friday, September 28th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $168.00 price target on shares of Edwards Lifesciences in a report on Friday, July 27th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $156.79.

Shares of NYSE:EW opened at $152.73 on Wednesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.31 and a quick ratio of 1.85. The stock has a market capitalization of $31.94 billion, a P/E ratio of 40.19, a PEG ratio of 2.01 and a beta of 0.87. Edwards Lifesciences Corp has a 52 week low of $103.01 and a 52 week high of $175.00.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, October 23rd. The medical research company reported $1.07 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.02 by $0.05. Edwards Lifesciences had a net margin of 20.67% and a return on equity of 30.11%. The company had revenue of $906.60 million during the quarter, compared to the consensus estimate of $927.56 million. During the same period last year, the firm earned $0.84 EPS. The company’s revenue for the quarter was up 10.4% on a year-over-year basis. On average, sell-side analysts anticipate that Edwards Lifesciences Corp will post 4.7 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Gulf International Bank UK Ltd Raises Holdings in Edwards Lifesciences Corp (EW)” was originally published by Week Herald and is the sole property of of Week Herald. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://weekherald.com/2018/11/07/gulf-international-bank-uk-ltd-raises-holdings-in-edwards-lifesciences-corp-ew.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Further Reading: Compound Interest and Why It Matters When Investing

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply